Osaka University · Faculty of Medicine / Graduate School of Medical Sciences

Research keywordshepatocellular carcinoma・liver fibrosis・portal hypertension・chronic hepatitis B・chronic hepatitis C・liver rehabilitation・immunotherapy resistance

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• Comparative analysis of lenvatinib use after atezolizumab plus bevacizumab versus lenvatinib as first-line therapy in unresectable hepatocellular carcinoma.2026 · Journal of gastroenterology Vol. 61 No. 1 p. 68-77 2026年1月 研究論文（学術雑誌）
• NRF2-COX2-PGE 2 axis drives immune cold tumors and predicts resistance to combination immunotherapy in hepatocellular carcinoma.2026 · Hepatology (Baltimore, Md.) 2026年1月15日 研究論文（学術雑誌）
• Auranofin, identified by FDA-approved drug library screening, inhibits HBs antigen secretion via lysosomal damage.2026 · PloS one Vol. 21 No. 1 2026年 研究論文（学術雑誌）
• Serum Growth Differentiation Factor 15 Can Be a Novel Biomarker to Predict the Prognosis of Patients With Hepatitis C Virus Cirrhosis After Virus Elimination.2026 · Hepatology research : the official journal of the Japan Society of Hepatology Vol. 56 No. 1 p. 21-32 2026年1月 研究論文（学術雑誌）

• Official profile